Presbyopia Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies – AbbVie, Orasis, Glaukos, LENZ Therapeutics, Eyenovia, Ocuphire, Novartis

Presbyopia Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies - AbbVie, Orasis, Glaukos, LENZ Therapeutics, Eyenovia, Ocuphire, Novartis
Delveinsight Business Research LLP
As per DelveInsight, the Presbyopia Market size was found to be USD 17,883 Million in the 7MM in 2021, which is anticipated to grow by 2032. The market is expected to grow owing to the expected launch of potential therapies and the rise in the increase in the prevalent population of Presbyopia in the 7MM.

The pipeline for Presbyopia is dynamic, consisting of Orasis Pharmaceuticals (PresbiDrops), Eyenovia (MicroLine), AbbVie (AGN-241622), Ocuphire Pharma (Nyxol), Visus therapeutics (Brimochol), and others therapies most of which are expected to launch during the forecast period [2022-2032]. Emerging therapies can potentially create a significant positive shift in the Presbyopia market size. Some of the leading pharma and biotech giants such as AbbVie, Eyenovia, Orasis Pharmaceuticals, Novartis, Visus Therapeutics, LENZ Therapeutics, Glaukos Corporation, Ocuphire Pharma, and others are actively working in the Presbyopia Market.

DelveInsight’s “Presbyopia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Presbyopia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Presbyopia market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Presbyopia Market

Presbyopia: An Overview

Presbyopia is a normal part of aging, wherein your eyes gradually lose the ability to see things up close. The term “presbyopia” comes from a Greek word that means “old eye.” Most people begin to notice the effect of presbyopia sometime after age 40 as the lenses of the eyes naturally lose their elasticity due to aging.

In Presbyopia, the shape of the crystalline lens of the eye changes. These changes make it difficult to focus on close objects. Presbyopia may seem to occur suddenly, but sight reduction occurs over several years. Presbyopia usually becomes noticeable in the early to mid-40s, but the reduction of your focus starts as early as childhood. 

Some signs of presbyopia include holding reading materials at arm’s length, blurred vision at normal reading distance, eye fatigue, and headaches when doing close work. Presbyopia happens naturally in people as they age. The eye cannot focus light directly on the retina due to the hardening of the natural lens. Aging also affects muscle fibers around the lens, making it harder for the eye to focus on up-close objects. The ineffective lens causes light to focus behind the retina, causing poor vision for objects that are up close.

Presbyopia Market Key Facts

  • The United States accounts for the largest market size of Presbyopia in comparison to EU5 (Germany, Italy, France, Spain, and the United Kingdom) and Japan.

  • Among the EU5 countries, Germany had the highest market size, with USD 1,936 million in 2021.

  • The total prevalent cases of Presbyopia in the 7MM were found to be 289,136,235 cases in 2021.

  • Among 7MM, the United States has the highest number of prevalent cases of Presbyopia, with 118,346,762 cases in 2021.

  • In EU-5, Germany had the highest prevalent population of Presbyopia with 36,822,212 cases, followed by Italy with 27,683,651 cases in 2021. On the other hand, Spain had the lowest prevalent population for 2021.

  • In 2021, Japan had 34,568,372 total prevalent cases of Presbyopia.

Presbyopia Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Presbyopia market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Presbyopia market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Presbyopia Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

The Report Covers the Presbyopia Epidemiology, Segmented as –

  • Total Diagnosed Cases of Presbyopia in the 7MM [2019–2032]

  • Total Age-Specific Cases of Presbyopia in the 7MM [2019–2032]

  • Total Prevalent Cases of Presbyopia in the 7MM [2019–2032]

  • Gender-Specific Cases of Presbyopia in the 7MM [2019–2032] 

  • Severity-Specific Cases of Presbyopia in the 7MM [2019–2032]

Presbyopia Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Presbyopia market or expected to be launched during the study period. The analysis covers the Presbyopia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Presbyopia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Presbyopia Market Will Evolve and Grow by 2032 @

Presbyopia Therapeutics Analysis

Several major pharma and biotech giants are developing therapies for Presbyopia. Several drugs are being developed as topical ophthalmic solutions to treat Presbyopia. These drops can broadly be divided into two categories: miotic-based eye drops and lens restoration drops.

Currently, Orasis Pharmaceuticals is leading the therapeutics market with its Presbyopia drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Presbyopia Therapeutic Market Include:

  • AbbVie

  • Cellix Bio

  • Eyenovia

  • Glaukos Corporation

  • JIXING Pharmaceuticals

  • LENZ Therapeutics

  • Novartis

  • Ocuphire Pharma

  • Orasis Pharmaceuticals

  • Visus Therapeutics

  • Vyluma

And Many Others

Presbyopia Emerging and Marketed Drugs Covered in the Report Include:

  • AGN-241622: AbbVie

  • CSF-1 (PresbiDrops): Orasis Pharmaceuticals

  • GLK-302 (Pilocarpine Ophthalmic Topical Cream): Glaukos Corporation

  • LNZ100 (Aceclidine 1.75%): LENZ Therapeutics

  • MicroLine (Pilocarpine Ophthalmic): Eyenovia

  • Nyxol: Ocuphire Pharma

  • UNR844 (Lipoic Acid Choline Ester): Novartis

  • VT-101 (Brimochol): Visus Therapeutics

  • Vuity: AbbVie

And Many More

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Presbyopia Competitive Intelligence Analysis

4. Presbyopia Market Overview at a Glance

5. Presbyopia Disease Background and Overview

6. Presbyopia Patient Journey

7. Presbyopia Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Presbyopia Treatment Algorithm, Current Treatment, and Medical Practices

9. Presbyopia Unmet Needs

10. Key Endpoints of Presbyopia Treatment

11. Presbyopia Marketed Products

12. Presbyopia Emerging Drugs and Latest Therapeutic Advances

13. Presbyopia Seven Major Market Analysis

14. Attribute Analysis

15. Presbyopia Market Outlook (In US, EU5, and Japan)

16. Presbyopia Access and Reimbursement Overview

17. KOL Views on the Presbyopia Market

18. Presbyopia Market Drivers

19. Presbyopia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @


Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Services and Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States